Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Fujisawa, Toshio ^a   Joshi, Bharat H ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BISULFITE; BUTYRIC ACID; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 13 RECEPTOR ALPHA2; MATRIX METALLOPROTEINASE; MESSENGER RNA; PSEUDOMONAS EXOTOXIN; SR 11302; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR AP 1; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; COMPLEMENTARY DNA; IMMUNOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PANCREAS CANCER; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIZATION; TUMOR MODEL; UPREGULATION; ACETYLATION; ANIMAL; DISEASE MODEL; DRUG SCREENING; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE;

ACETYLATION; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13; MATRIX METALLOPROTEINASES; MICE; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERLEUKIN-13; TRANSCRIPTION FACTOR AP-1; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953742165     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-37     Document Type: Article

References (34)

1. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res 2006, 66:4434-4442. 10.1158/0008-5472.CAN-05-1265, 16618770.
2. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32. 10.1034/j.1600-065X.2002.18803.x, 12445278.
3. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001, 92:168-175. 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N, 11291041.
4. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996, 87:4333-4339.
5. Kawakami K, Husain SR, Kawakami M, Puri RK. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002, 8:487-494. 2040009, 12435859.
6. Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997, 3:151-156.
7. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006, 107:1407-1418. 10.1002/cncr.22134, 16902988.
8. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995, 1:1253-1258.
9. Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270:16775-16780. 10.1074/jbc.270.28.16775, 7622490.
10. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002, 8:1948-1956.
11. Joshi BH, Puri RK. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005, 39:189-198. 10.1016/j.pep.2004.10.012, 15642470.
12. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004, 101:1004-1011. 10.3171/jns.2004.101.6.1004, 15597761.
13. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006, 74:479-504.
14. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25:837-844. 10.1200/JCO.2006.08.1117, 17327604.
15. Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin Cancer Res 2009, 16:577-586.
16. Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK. Targeting IL-13Ralpha2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2010,
17. Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Puri RK, Russell SJ, Galanis E. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 2008, 16:1556-1564. 10.1038/mt.2008.152, 2748750, 18665158.
18. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166. 10.1158/0008-5472.CAN-04-0454, 15604287.
19. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463. 10.1038/nature02625, 15164071.
20. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 2009, 8:1056-1072. 10.1016/S1474-4422(09)70262-5, 19833297.
21. Lennartsson A, Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta 2009, 1790:863-868.
22. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398. 10.1038/nature05913, 17522671.
23. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002, 3:224-229. 10.1093/embo-reports/kvf053, 1084017, 11882541.
24. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2:150-157.
25. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005, 4:549-551. 10.4161/cc.4.4.1564, 15738652.
26. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39. 10.1182/blood-2006-06-025999, 1785068, 16960145.
27. Joshi BH, Husain SR, Puri RK. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. Drug News Perspect 2000, 13:599-605. 10.1358/dnp.2000.13.10.858450, 12879131.
28. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009, 69:8678-8685. 10.1158/0008-5472.CAN-09-2100, 19887609.
29. Joshi BH, Leland P, Calvo A, Green JE, Puri RK. Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. Cancer Res 2008, 68:9311-9317. 10.1158/0008-5472.CAN-08-2810, 19010904.
30. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000, 60:1168-1172.
31. Kawakami K, Kawakami M, Husain SR, Puri RK. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo. Gene Ther 2003, 10:1116-1128. 10.1038/sj.gt.3301956, 12808442.
32. Wu AH, Low WC. Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. Neuro Oncol 2003, 5:179-187. 10.1215/S1152851702000510, 1920687, 12816724.
33. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP, Rifkind RA, Marks PA, Richon VM, Pandolfi PP. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001, 108:1321-1330. 209432, 11696577.
34. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009, 69:8693-8699. 10.1158/0008-5472.CAN-09-1456, 2779578, 19861533.